Results 21 to 30 of about 18,118,892 (286)

Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040.

open access: yesValue in Health, 2015
OBJECTIVES To estimate the loss in quality-adjusted life-years (QALYs) in Korean adults due to 13 noncommunicable diseases (NCDs) in 2010 and predict changes in QALY loss through to the year 2040. METHODS Thirteen NCDs (hypertension, diabetes mellitus,
M. Ock   +4 more
semanticscholar   +3 more sources

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

open access: yesClinicoEconomics and Outcomes Research, 2013
Montarat Thavorncharoensap,1,2 Yot Teerawattananon,2 Sirin Natanant,2 Wantanee Kulpeng,2 Jomkwan Yothasamut,2 Pitsaphun Werayingyong21Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand; 2Health Intervention and Technology ...
Thavorncharoensap M   +5 more
doaj   +2 more sources

Multivariate risk preferences in the quality-adjusted life year model. [PDF]

open access: yesHealth Econ, 2022
International audienceThe interest in multivariate and higher-order risk preferences has increased. A growing body of literature has demonstrated the relevance and impact of these preferences, but for health the evidence is lacking.
Attema AE, Frasch JJ, L'Haridon O.
europepmc   +2 more sources

Habilitation of Child with Spinal Muscular Atrophy Type 2: A Case Report

open access: yesSurabaya Physical Medicine and Rehabilitation Journal, 2022
Spinal Muscular atrophy (SMA) is a severe neuromuscular disorder which is a hereditary genetic disease. It is an incurable disease due to a defect in the survival motor neuron 1 (SMN1) gene.
Marietta Shanti Prananta   +2 more
doaj   +1 more source

Effects of Chronic Diseases on Quality Adjusted Life Year and Economic Losses of the Elderly [PDF]

open access: yesZhongguo quanke yixue, 2022
Background Chronic diseases have become an important public health problem that affects the economic and social development of country and population health. Quantifying the disease and economic burden of the elderly can provide a better understanding of
Xinyue ZHAO, Xiao ZHENG, Yaqing XUE, Weiwei WU, Jiao LU, Chichen ZHANG
doaj   +1 more source

Economic burden of the novel coronavirus infection: a systematic review

open access: yesФармакоэкономика, 2022
Background. The sudden emergence and rapid spread of the novel coronavirus infection (COVID-19) caused tremendous burden on the health care system including the economic one.
V. M. Timiryanova   +3 more
doaj   +1 more source

Measuring the Benefits of Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions [PDF]

open access: yesInternational Journal of Health Policy and Management, 2018
Background The measurement of health benefits is a key issue in health economic evaluations. There is very scarce empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as ...
Federico Augustovski   +8 more
doaj   +1 more source

Cost-Effectiveness of Physical Rehabilitation and Care of Older Home-Dwelling Persons after Hip Fracture: A Systematic Review and Narrative Synthesis

open access: yesJournal of Rehabilitation Medicine, 2022
Objective: To provide a systematic review of the literature and knowledge base of cost per quality-adjusted life year of physical rehabilitation and care of older persons after hip fracture.
Jonas Ammundsen Ipsen   +5 more
doaj   +1 more source

The application of the QALY measure in the assessment of the effects of health interventions on an older population: a systematic scoping review

open access: yesArchives of Public Health, 2021
Background One of the most commonly used types of evaluation methods is cost-utility analysis (CUA), using the Quality Adjusted Life Year (QALY) indicator as a preference-based measure for assessing effects of a given programme.
Ewa Kocot   +2 more
doaj   +1 more source

Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis

open access: yesLiver Cancer, 2020
Introduction: Hepatocellular carcinoma (HCC) is the most common form of liver cancer worldwide and carries a poor prognosis. Historically, sorafenib was the only available systemic treatment for advanced HCC.
Christopher Sherrow   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy